“Primary Immune Deficiency (PID) – Pipeline Insight, 2019” report outlays comprehensive insights of present scenario and growth prospects across Primary Immune Deficiency (PID). A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.
Products covered by Phase • Phase III, Phase II, Phase I
• Pre-clinical & Discovery
• Inactive (Discontinued and Dormant)
Overview of pipeline development activities for Primary Immune Deficiency (PID)
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.
Therapeutic segmentation of products for Primary Immune Deficiency (PID)
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this indication.
Methodology Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Scope of the report • Provides an overview of therapeutic pipeline activity for Primary Immune Deficiency (PID) across the complete product development cycle including all clinical and non-clinical stages
• It comprises of detailed profiles of Primary Immune Deficiency (PID) therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
• Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across Primary Immune Deficiency (PID)
Reasons to Buy • Establish a comprehensive understanding of the current pipeline scenario across Primary Immune Deficiency (PID) to formulate effective R&D strategies
• Assess challenges and opportunities that influence Primary Immune Deficiency (PID) R&D
• Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the product and use it for target finding, drug repurposing, and precision medicine
• Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Primary Immune Deficiency (PID) to enhance and expand business potential and scope
• Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
Our reports have been used by over 10K customers, including:
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
Proton Therapy Market Size, Share, Global Forecast 2022-2027, Industry Trends, Impact of COVID-19, Opportunity Company Analysis Proton therapy is a type of radiation called proton beam radiation therapy it is safer and more effective than conventional radiation therapy for adults with advanced stages cancer. Since,...
This research service provides an overview of the global TDx market and a 4-year forecast of it from 2021 to 2025. The market will reach $8,848.6 million in 2025, growing at a compound annual growth rate (CAGR) of 8.9% from 2020 to 2025. The advanced staining and anatomical pathology laboratory information management systems (APLIS) segments...
Anatomic Pathology market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Anatomic Pathology Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Anatomic Pathology types, applications. Further, Anatomic Pathology...
Anatomic Pathology Track and Trace Solutions market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Anatomic Pathology Track and Trace Solutions Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Anatomic Pathology...
Pathology Devices market is one of the high-growth prospect industries with potential opportunities throughout 2028. The Pathology Devices Market growth analysis and insights report analyzes emerging market trends, market size outlook, potential opportunities, market share by Pathology Devices types, applications. Further, Pathology Devices...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the 3D printed implants market are 3D Systems Corporations, Stratasys Ltd, Arcam AB, EnvisionTEC and SLM Solutions Group AG. The global 3D printed implants market is expected to grow from $0.14 billion in 2020 to $0.15 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies...
The global apheresis equipment market exhibited strong growth during 2015-2020. Looking forward, the analyst expects the market to grow at a CAGR of 8.8% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.